Search results: (10000)
News Dual therapy improves not only lung function but also quality of life in COPD patients
Chronic obstructive pulmonary disease (COPD) reduces the quality of life of patients and is one of the main causes of morbidity and mortality. According to international recommendations, the initial pharmacotherapy is recommended as monotherapy with LAMA (long-acting muscarinic antagonists) or LABA (long-acting beta-agonists), or their combination. A pooled analysis of 4 studies compared the early addition of LABA to LAMA in patients with moderate to severe COPD.
News Chairwoman of Revma Liga ČR: I Hope We Improve Our Approach and Treatment of Osteoporosis in the Czech Republic
Patients with inflammatory rheumatic diseases have a significantly increased risk of developing osteoporosis and related fractures. At the same time, this disease is considerably underestimated in the Czech Republic, and more attention is given to it only at the stage of osteoporotic fractures. To what extent does the patient organization Revma Liga ČR, which unites patients with rheumatic diseases, engage in this issue? We asked its chairwoman Edita Müllerová.
News Adequate Anti-Xa Levels Are More Often Achieved in Trauma Patients When Dosing Enoxaparin Based on Weight
Thromboembolic disease (TED) is a well-known preventable cause of morbidity and mortality in trauma patients. To improve their prognosis, pharmacological thromboprophylaxis, such as with low molecular weight heparins (LMWH), is an essential part of treatment. However, previously published studies have pointed out that standard dosing of LMWH may be associated with insufficient levels of activity measured using the anti-Xa parameter.
News Romiplostim Before Splenectomy in a Patient with ITP - Case Report
In the following case report from authors at a university hospital in Barcelona, the successful use of romiplostim as a second-line treatment before planned splenectomy in a patient with immune thrombocytopenia (ITP), liver cirrhosis, and iatrogenic Cushing's syndrome is demonstrated.
News Biosimilar Drugs in Oncology
8 of the 10 most expensive drugs on the market are used in the treatment of cancer. Rising healthcare costs in recent decades have created a need to find strategies to limit these costs. Biosimilar preparations have the potential to partially replace existing original biological drugs and reduce the cost of cancer treatment. We therefore briefly summarize the basic information on the issue of biosimilars in terms of their benefits, safety, and interchangeability.
News Neuroprotective Efficacy and Safety of Vinpocetine in Patients with Acute Ischemic Stroke
A meta-analysis of 4 randomized placebo-controlled studies demonstrated the benefits of vinpocetine in patients with ischemic stroke (iCMP). Administering vinpocetine within 14 days of the onset of the stroke significantly reduced the level of disability and the proportion of those who died or were dependent on others after 1 and 3 months. The results showed benefits in several other parameters and indicated very good tolerability of this drug used to increase cerebral blood flow.
News Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to severe ulcerative colitis (UC) and continues to undergo intensive clinical research. The DAYBREAK open-label, single-arm study for participants with RRMS from previous trials with ozanimod was scheduled to be completed by January 2023, and its final results can therefore be expected soon. The following article presents the interim analysis results of this study 5 years after initiation.
News Teriflunomide and Pregnancy Planning
The authors of the article published last year in Multiple Sclerosis Journal present data regarding experiences with the use of teriflunomide during pregnancy.
News Bone density in hemophiliacs − known and less-known risk factors
Osteopenia or osteoporosis are known comorbidities of hemophilia and concern many of these patients. What all contributes to their development?
News Risk of Developing Inhibitors in People with Milder Forms of Hemophilia
Moderate and mild hemophilia A differ from the severe form not only in clinical course and bleeding risk, but also in the risk of developing neutralizing antibodies (inhibitors).
News Von Willebrand Disease as a Cause of Abnormal Uterine Bleeding
Abnormal uterine bleeding constitutes a large portion of complaints among women of reproductive age. This type of bleeding is typical for von Willebrand disease (vWD), but also for other types of coagulation disorders. So, is vWD more frequent in women with abnormal uterine bleeding than in the general population?
News Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment
With the development of new treatment options for hemophilia, there has also been progress in methods for monitoring hemophilic arthropathy and identifying it in its early stages. In addition to classical X-rays, clinical scoring systems, and the gold standard of magnetic resonance imaging (MRI), the so-called POCUS – point-of-care ultrasound – has emerged as a quick and reliable method for assessing joint health. Potential biomarkers for osteochondral damage and synovial proliferation specific to hemophilia or for detecting joint bleeding are also being investigated, though their routine use is not anticipated in the near future.
News Efficacy of L. reuteri DSM 17938 in the Treatment of Infantile Colic
Infantile colic represents a syndrome of behavioral disorders in infants characterized by episodes of uncontrollable crying, wailing, and restlessness without an identifiable cause. This is a common health issue affecting an estimated 5–40% of infants. There are no uniform criteria for the treatment of this benign condition yet, but available studies show a beneficial effect from administering probiotics containing Limosilactobacillus reuteri (previously known as Lactobacillus reuteri) compared with placebo and other treatment methods.
News Intestinal Gel LECIG in the Treatment of Advanced Parkinson's Disease in Real Practice
A recently published study presents the first experiences with an intestinal gel containing a triple combination of antiparkinsonian drugs and dosed via an infusion pump through percutaneous endoscopic gastrostomy extended into the jejunum in the treatment of advanced Parkinson's disease.
News Position of Enoxaparin and DOACs in Extended Prevention of VTE After Surgeries for Gynecological Malignancies
The prophylaxis of venous thromboembolism is a crucial part of postoperative management in oncological diseases, including gynecological malignancies. A newly published survey study conducted in Australia and New Zealand focused precisely on these. The authors were interested in different types of postoperative prophylactic regimens and the potential use of direct oral anticoagulants (DOACs) in them.
News Risk of Venous Thromboembolism and CV Events during Targeted Treatment of Nonspecific Bowel Inflammations
Authors of a freshly published study based on real-world data from the USA investigated whether there are differences in the risk of venous thromboembolism (VTE) and major cardiovascular (CV) events in patients with nonspecific bowel inflammations (IBD) who were newly prescribed the Janus kinase inhibitor (JAK) tofacitinib or the tumor necrosis factor-alpha (TNF-α) inhibitor.
News How to Secure Diabetics with Atrial Fibrillation During PCI?
Optimal management of patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) continues to be the subject of studies. A sub-analysis of the RE-DUAL study focused on this issue in a high-risk group of patients with diabetes.
News Physiotherapy as Part of Comprehensive Care for People with Hemophilia – Recommendations vs. Reality
It appears that the physiotherapeutic care provided in reality to people with hemophilia does not align with current recommendations, which see it as an integral part of a multidisciplinary approach. Therefore, in the summer of 2020, an initiative of experts from various countries, including the Czech Republic, was formed to address this issue.
News Are there mutual interactions between candesartan and amlodipine in the combination therapy of hypertension?
Monotherapy is often insufficient in the treatment of hypertension; however, combining antihypertensives with different mechanisms of action can be complicated by their mutual interactions. Therefore, a study by South Korean authors examined the pharmacokinetic interactions between candesartan and amlodipine, substances that are commonly used together in combined treatment.
News Sequential administration of immunochemotherapy and venetoclax after failure of BCR inhibitor treatment – interactive video case study
The treatment of chronic lymphocytic leukemia (CLL) is evolving. What was impossible years ago is now becoming a reality. From chemotherapy, through immunochemotherapy, to the use of molecules targeting apoptotic pathways of tumor cells, the prognosis for patients has markedly improved. However, the wide therapeutic spectrum also brings its own specifics and complications, and the correct sequencing of treatment lines and their selection for each individual is necessary, considering the nature of CLL, overall condition, and comorbidities.
News ESC 2022: SGLT2 Inhibitors as Hope for HFpEF: How to Implement Them in Practice?
Patients with heart failure (HF) can significantly benefit from the inclusion of sodium-glucose co-transporter 2 inhibitors (SGLT2i, i.e., gliflozins) in their treatment strategy according to current findings. This also applies to patients with preserved left ventricular ejection fraction (HFpEF). At the ESC 2022 congress, useful information for practical applications was presented in addition to study data. For illustration, we bring a case study from a German practice.
News Undiagnosed Hereditary Angioedema in Pregnancy – Case Study
Delayed diagnosis or misdiagnosis is not uncommon with hereditary angioedema (HAE), especially during pregnancy and the postpartum period. A case study by Canadian authors illustrates that HAE should be considered in the differential diagnosis for any patient with unexplained abdominal pain and recurrent swellings without the presence of urticaria.
News Polatuzumab Vedotin in the Treatment of NHL - News from the 25th EHA Congress
Polatuzumab vedotin (Polivy) is approved in the EU for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), for whom hematopoietic stem cell transplantation (HSCT) is not suitable. We provide an overview of the latest news regarding the role of this modern medicine in the therapy of non-Hodgkin's lymphomas (NHL), presented at the 25th Congress of the European Hematology Association (EHA), held virtually due to the pandemic situation.
News PID in children manifest differently, 10 warning signs help in diagnosis
We asked MUDr. Eva Hlaváčková from the Department of Clinical Immunology and Allergology, Faculty of Medicine, Masaryk University, and St. Anne's University Hospital in Brno about the essential details regarding the 10 warning signs of primary immunodeficiencies (PID) and in which cases the vaccination schedule needs to be adapted for sick children.